CMX001 combines Chimerix’s Lipid-Antiviral-Conjugate Technology with cidofovir, an approved antiviral agent, with the aim of creating a well-tolerated and highly potent new chemical entity with broad-spectrum antiviral activity. We believe that if we can successfully develop a product with increased efficacy and reduced toxicities we can provide a powerful new option for patients and their physicians that may dramatically change antiviral treatment, particularly among immunocompromised patients. In clinical testing to date, CMX001 has shown oral bioavailability in humans and has demonstrated a positive safety profile.
We are currently conducting clinical trials of CMX001 for the treatment of dsDNA viruses in immunocompromised transplant patients.
CMX001 is a mimic of a naturally occurring lipid, lysolecithin, formed by linking a lipid, 3-hexadecyloxy-1-propanol, to the phosphonate group of cidofovir. CMX001 is designed to readily cross the intestinal wall and penetrate target cells before being cleaved to free the antiviral, cidofovir. Cidofovir is phosphorylated by host cell nucleoside kinases to form the active antiviral agent cidofovir diphosphate.
himerix has completed a Phase 1 clinical study of orally-administered CMX001 in 84 healthy volunteers. The blinded, randomized, parallel-group, placebo-controlled study evaluated the safety and pharmacokinetics of single and multiple doses of CMX001. CMX001 was well tolerated at all doses. In addition, CMX001 was well absorbed after oral dosing, with dose-dependent pharmacokinetics. Read More
Chimerix has amassed an unusual breadth of assets with considerable potential in antiviral innovation, including our PIM (Phospholipid Intramembrane Microfluidization) Conjugate Technology and the Townsend Chemical Library. The combination of our team’s internal antiviral product expertise with a number of internally-generated leads against several important viruses allows us the flexibility to pursue out-licensing or co-development partners for our emergent antiviral medicines. Read More